Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The FEBS Journal|November 4, 2016
Targeting mutant p53 in cancer: a long road to precision therapyFiamma Mantovani, Dawid Walerych, Giannino Del Sal
Molecular & Cellular Oncology|February 16, 2017
Mutant p53-Nrf2 axis regulates the proteasome machinery in cancerKamil Lisek, Dawid Walerych, Giannino Del Sal
Frontiers in Oncology|January 7, 2016
Mutant p53: One, No One, and One Hundred ThousandDawid Walerych, Kamil Lisek, Giannino Del Sal
Sub-Cellular Biochemistry|September 10, 2014
Cooperation of p53 mutations with other oncogenic alterations in cancerJavier E Girardini, Dawid Walerych, Giannino Del Sal
Carcinogenesis|July 24, 2012
The rebel angel: mutant p53 as the driving oncogene in breast cancerDawid Walerych, Marco Napoli, Licio Collavin, et al.
The Journal of Biological Chemistry|September 11, 2004
Hsp90 regulates the activity of wild type p53 under physiological and elevated temperaturesLin Müller, Andreas Schaupp, Dawid Walerych, et al.
Frontiers in Molecular Neuroscience|May 31, 2021
Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN DeficiencyKatarzyna Gaweda-Walerych, Dawid Walerych, Mariusz Berdyński, et al.
Oncotarget|May 15, 2018
Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cellsKamil Lisek, Elena Campaner, Yari Ciani, et al.
Oncotarget|September 4, 2018
Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanismDawid Walerych, Magdalena Pruszko, Lukasz Zyla, et al.
Cancers|June 18, 2020
A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human CancerMaria Grzes, Magdalena Oron, Zuzanna Staszczak, et al.
Pageof 2